News

Researchers have found that amyloid, the protein that forms toxic aggregates, or clumps in the brain and is thought to be involved in the onset of Alzheimer’s disease (AD), accumulates faster in people with subtle cognitive difficulties compared with cognitively normal people. These findings suggest that measurements of…

DNA from various species of bacteria, some of which — like E. coli — have been identified in the brains of Alzheimer’s patients, can cause the tau protein to fold incorrectly and form the toxic, clump-like structures increasingly thought to play a key role in disease progression. The study…

A new biosensor using neatly aligned carbon nanotubes may bring scientists one step closer to a blood test for the early detection of Alzheimer’s disease. The nanotubes were able to measure microscopic concentrations of Alzheimer’s main protein biomarkers in blood plasma, and reportedly distinguished Alzheimer’s patients from healthy…

A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB). The DSMB reviewed safety data, enrollment, participant status,…

Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in a Phase 2/3 clinical trial (NCT01760005). Despite these results, the data collected will prove useful for identifying…

Biogen will soon launch an open-label trial to start re-dosing aducanumab  — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted in March 2019. The company said it submitted the protocol of the re-dosing study to the U.S.

The number of people with dementia in 37 countries in and near Europe is likely to double to 18.8 million by 2050, according to Alzheimer Europe. That’s more than the 18 million predicted in previous forecasts. The Luxembourg-based organization also lowered estimates of the current dementia count by a…

Following feedback from the U.S. Food and Drug Administration (FDA), Cortexyme will conduct an interim analysis for effectiveness of its lead investigational therapy COR388, currently in the Phase 2/3 GAIN trial for treatment of mild to moderate Alzheimer’s disease. The analysis, expected to be finished by the end…

Using the gene editing technology CRISPR-Cas9 like a pair of “DNA scissors,” researchers were able to essentially cut out the beta-secretase 1 (BACE1) gene in a mouse model of Alzheimer’s disease, a study shows. Deleting this gene — which drives the production of amyloid-β proteins in…

A molecular chaperone called TPT-172 was able to prevent proteins linked to Alzheimer’s — including amyloid-beta and tau — from building up in the brain, improve memory and ease brain inflammation when tested in a mouse model of the disease. The study, “A pharmacological chaperone improves memory by…